source
- Akeso and Summit’s lung cancer candidate shows worsening tumor progression, while Europe halts Tavneos over trial concernsAkeso Therapeutics and Summit Therapeutics reported that their combined lung cancer therapy failed to improve outcomes, with data indicating a worsening in tumor progression compared to control. T…
- AstraZeneca halts late-stage trial of volrustomig in metastatic lung cancerAstraZeneca said it is stopping a late-stage study of its experimental drug volrustomig combined with chemotherapy in patients with metastatic non-small cell lung cancer. The company made the decis…